Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00474513 |
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many diseases. GSK239512 is a drug that binds to the Histamine 3 receptor (a protein) in the brain (receptor occupancy). This study will use the technique of positron emission tomography (PET) as an imaging tool to highlight areas of the brain that GSK239512 has penetrated, and subsequently bound to receptors, after receiving an oral dose of the drug. It will also look at the rate the drug dissociates from the receptors in the brain. Results from the study will provide information on doses of the drug to be given in further studies.
Condition | Intervention | Phase |
---|---|---|
Mild Cognitive Impairment |
Drug: GSK239512 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Pharmacodynamics Study |
Official Title: | A PET Study Using [11C] GSK189254 to Establish the Dose, Plasma Concentration and Brain Receptor Occupancy Relationship of GSK239512, a Histamine H3 Antagonist, in Healthy Subjects |
Enrollment: | 5 |
Study Start Date: | March 2007 |
Study Completion Date: | March 2008 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 35 Years to 49 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | H3B106026 |
Study First Received: | May 15, 2007 |
Last Updated: | October 27, 2008 |
ClinicalTrials.gov Identifier: | NCT00474513 History of Changes |
Health Authority: | Canada: Health Canada |
AD, H3, Brain, Cognitive Impairment |
Neurotransmitter Agents Delirium, Dementia, Amnestic, Cognitive Disorders Histamine Antagonists Mental Disorders Histamine phosphate Healthy |
Dementia Histamine H3 Antagonists Cognition Disorders Histamine Delirium |
Neurotransmitter Agents Delirium, Dementia, Amnestic, Cognitive Disorders Molecular Mechanisms of Pharmacological Action Histamine Antagonists Mental Disorders |
Physiological Effects of Drugs Histamine Agents Histamine H3 Antagonists Pharmacologic Actions Cognition Disorders |